SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 9.99% Passive Stake in Sunshine Biopharma Inc.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 9.99% in Sunshine Biopharma Inc. through a Schedule 13G filing.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Sunshine Biopharma Inc.
• As of May 23, 2025, the Reporting Persons collectively beneficially own 505,653 shares of Sunshine Biopharma Inc. common stock.
• This ownership represents approximately 9.99% of the company's common stock.
• The shares are issuable upon the exercise of a warrant held by Intracoastal Capital LLC (the "Intracoastal Warrant").
• The Intracoastal Warrant includes a "blocker provision" that prevents its exercise to the extent that such exercise would result in beneficial ownership by the holder and its affiliates exceeding 9.99% of the common stock.
• Without this blocker provision, the Reporting Persons could have beneficially owned 2,426,509 shares.
• The beneficial ownership calculation is based on 4,555,945 shares of common stock outstanding as of May 15, 2025, as reported by the Issuer, plus the 505,653 shares issuable from the Intracoastal Warrant.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, as required by SEC regulations. It does not contain positive or negative operational or financial news about the company itself, nor does it indicate any intent to influence or control the company.

Positives

• The filing indicates a significant, albeit passive, investment by Intracoastal Capital LLC and its principals, which could be interpreted as a vote of confidence in Sunshine Biopharma Inc.

Future Outlook

No forward-looking statements or guidance are provided in this ownership disclosure.

Management Comments

• "The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements."
• "The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of passive ownership and does not provide information to analyze broader industry trends or competitors. It indicates an investment in a biopharma company.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory disclosure of passive ownership.
• It does not contain information that allows for a comparison of Sunshine Biopharma Inc.'s operational or financial results against industry benchmarks or specific comparable companies/projects.
• The ownership percentage of 9.99% is just below the 10% threshold that would typically trigger a Schedule 13D filing (which implies intent to influence or control), aligning with the passive nature of a 13G.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive shareholder group. The blocker provision ensures that this group's ownership remains below 10%, which might be viewed positively by some shareholders as it limits potential control shifts without a more detailed 13D filing.
• Management: Awareness of a significant passive investor group.

Key Dates

Keywords

Sunshine Biopharma Inc., Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, beneficial ownership, common stock, warrant, passive investment, SEC filing, biopharma